Neuroendocrine Carcinomas (NEC)
5 clinical trials · Condition
◉ Watch Neuroendocrine Carcinomas (NEC)
| Record | Firm | Date |
|---|---|---|
| Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine Carcinoma (NCT07156019) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2025-10-01 |
| Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients (NCT06893783) | Inkeun Park | 2025-09-02 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma (NCT07014540) | Beijing GoBroad Hospital | 2025-06-20 |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686) | Phanes Therapeutics | 2023-09-05 |
| A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours (NCT04525638) | Fundación de investigación HM | 2020-06-29 |
Track Neuroendocrine Carcinomas (NEC) automatically
Every clearance here is in the API, with alerts when new ones post.